Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective. J Pediatric Infect Dis Soc 2024 Feb 28;13(Supplement_1):S68-S79
Date
02/28/2024Pubmed ID
38417087DOI
10.1093/jpids/piad115Scopus ID
2-s2.0-85186459019 (requires institutional sign-in at Scopus site)Abstract
Invasive fungal disease (IFD) remains a significant cause of morbidity and mortality in children undergoing transplantation. There is a growing armamentarium of novel antifungal agents recently approved for use or in late stages of clinical development. The overarching goal of this review is to discuss the mechanisms of action, spectrum of activity, stage of development, and pediatric-specific data for the following agents: encochleated amphotericin B deoxycholate, fosmanogepix, ibrexafungerp, isavuconazole, olorofim, opelconazole, oteseconazole, and rezafungin. Additionally, key drug attributes of these novel agents and their potential future therapeutic roles in pediatric transplant recipients are discussed.
Author List
Hsu AJ, Hanisch BR, Fisher BT, Huppler ARAuthor
Anna H. Huppler MD Associate Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antifungal AgentsChild
Humans
Invasive Fungal Infections
Mycoses
Transplant Recipients
